Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis

Summary Background Fibroblast growth factor 21 (FGF21) analogues have emerged as promising therapeutic targets for non‐alcoholic steatohepatitis (NASH). However, the effects and safety of these analogues on NASH and NASH‐related fibrosis remain unexplored. Aims To estimate the efficacy and safety of FGF21 analogues for treating NASH and NASH‐related fibrosis. Methods PubMed, Embase, and the Cochrane Library were searched for relevant studies up to 11 October 2023. Primary outcomes were defined as the fibrosis improvement ≥1 stage without worsening of NASH and NASH resolution without worsening fibrosis. Secondary outcomes included biomarkers of fibrosis, liver injury, and metabolism. Treatment‐related adverse events were also analysed. Results Nine studies, including 1054 patients with biopsy‐proven NASH and stage F1–F4 fibrosis, were identified. Seven studies reported histological outcomes. The relative risk (RR) for obtaining fibrosis improvement ≥1 stage efficacy was 1.79 (95% CI 1.29–2.48, I 2 = 37%, p < 0.001) with FGF21 analogues relative to placebo. Although no statistically significant difference was observed between FGF21 analogues in NASH resolution, sensitivity analyses and fragility index suggest that this result is unstable. The drugs improved hepatic fat fraction (HFF), along with other biomarkers of fibrosis, liver injury, and metabolism (MRE, LSM, Pro‐C3, ELF, ALT, AST, TG, HDL‐C, and LDL‐C). Additionally, no significant difference in serious adverse event incidence rate was observed (RR = 1.26, 95% CI 0.82–1.94, I 2 = 24%, p = 0.3). Conclusions FGF21 analogues appear as promising agents for the treatment of NASH and NASH‐related fibrosis, and they generally seem to be safe and well tolerated.